keyword
MENU ▼
Read by QxMD icon Read
search

Robert soslow

keyword
https://www.readbyqxmd.com/read/29671892/frequent-loss-of-claudin-4-expression-in-dedifferentiated-and-undifferentiated-endometrial-carcinomas
#1
Basile Tessier-Cloutier, Robert A Soslow, Colin J R Stewart, Martin Köbel, Cheng-Han Lee
INTRO: Dedifferentiated/undifferentiated endometrial carcinomas (DDEC/UEC) are aggressive endometrial cancers with frequent genomic inactivation of core components of switch/sucrose non-fermentable (SWI/SNF) complex proteins. Claudin-4, an epithelial intercellular tight junction protein was recently found to be expressed in SWI/SNF-deficient undifferentiated carcinomas but not SWI/SNF-deficient sarcomas. The aim of this study is to examine claudin-4 expression in UEC/DDEC and other high-grade uterine carcinomas...
April 19, 2018: Histopathology
https://www.readbyqxmd.com/read/29561302/international-study-of-primary-mucinous-ovarian-carcinomas-managed-at-tertiary-medical-centers
#2
Jennifer J Mueller, Henrik Lajer, Berit Jul Mosgaard, Slim Bach Hamba, Philippe Morice, Sebastien Gouy, Yaser Hussein, Robert A Soslow, Brooke A Schlappe, Qin C Zhou, Alexia Iasonos, Claus Høgdall, Alexandra Leary, Roisin E OʼCearbhaill, Nadeem R Abu-Rustum
OBJECTIVE: We sought to describe a large, international cohort of patients diagnosed with primary mucinous ovarian carcinoma (PMOC) across 3 tertiary medical centers to evaluate differences in patient characteristics, surgical/adjuvant treatment strategies, and oncologic outcomes. METHODS: This was a retrospective review spanning 1976-2014. All tumors were centrally reviewed by an expert gynecologic pathologist. Each center used a combination of clinical and histologic criteria to confirm a PMOC diagnosis...
March 21, 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29553955/ntrk-fusions-define-a-novel-uterine-sarcoma-subtype-with-features-of-fibrosarcoma
#3
Sarah Chiang, Paolo Cotzia, David M Hyman, Alexander Drilon, William D Tap, Lei Zhang, Jaclyn F Hechtman, Denise Frosina, Achim A Jungbluth, Rajmohan Murali, Kay J Park, Robert A Soslow, Esther Oliva, A John Iafrate, Ryma Benayed, Marc Ladanyi, Cristina R Antonescu
Tropomyosin receptor kinase (Trk) inhibitors have shown high response rates in patients with tumors harboring NTRK fusions. We identified 4 NTRK fusion-positive uterine sarcomas that should be distinguished from leiomyosarcoma and undifferentiated uterine sarcoma. NTRK rearrangements were detected by fluorescence in situ hybridization (FISH) and/or targeted RNA or DNA sequencing in 4 undifferentiated uterine sarcomas with spindle cell morphology. Because of histologic overlap with leiomyosarcoma, TrkA and pan-Trk immunohistochemistry was performed in 97 uterine leiomyosarcomas...
March 16, 2018: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29531130/transducin-like-enhancer-of-split-3-tle3-expression-is-associated-with-taxane-sensitivity-in-non-serous-ovarian-carcinoma-in-a-three-cohort-study
#4
Brian Z Ring, Rajmohan Murali, Robert A Soslow, David D L Bowtell, Sian Fereday, Anna DeFazio, Nadia Traficante, Catherine J Kennedy, Alison Brand, Raghwa Sharma, Paul Harnett, Goli Samimi
BACKGROUND: Chemo-resistance is a major challenge in ovarian cancer treatment, resulting in poor survival rates. Identifying markers of treatment response is imperative for improving outcome while minimizing unnecessary side effects. We have previously demonstrated that expression of transducin-like enhancer of split 3 (TLE3) is associated with favorable progression-free survival in taxane-treated ovarian cancer patients with non-serous histology. The purpose of this study was to perform an independent evaluation of the association of TLE3 expression with response to taxane-based chemotherapy in non-serous ovarian cancer, to validate its role as a potential therapeutic response marker for taxane-based chemotherapy...
March 12, 2018: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/29517499/interpretation-of-p53-immunohistochemistry-in-endometrial-carcinomas-toward-increased-reproducibility
#5
Martin Köbel, Brigitte M Ronnett, Naveena Singh, Robert A Soslow, C Blake Gilks, W Glenn McCluggage
P53 immunohistochemistry has evolved into an accurate surrogate reflecting the underlying TP53 mutation status of a tumor, and has utility in the diagnostic workup of endometrial carcinomas. Recent work predominantly carried out in tubo-ovarian high-grade serous carcinoma has revealed 4 main patterns of p53 staining (normal/wild-type, complete absence, overexpression, and cytoplasmic); the latter 3 patterns are variably termed abnormal/aberrant/mutation-type and are strongly predictive of an underlying TP53 mutation...
March 6, 2018: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/29505428/molecular-classification-of-grade-3-endometrioid-endometrial-cancers-identifies-distinct-prognostic-subgroups
#6
Tjalling Bosse, Remi A Nout, Jessica N McAlpine, Melissa K McConechy, Heidi Britton, Yaser R Hussein, Carlene Gonzalez, Raji Ganesan, Jane C Steele, Beth T Harrison, Esther Oliva, August Vidal, Xavier Matias-Guiu, Nadeem R Abu-Rustum, Douglas A Levine, C Blake Gilks, Robert A Soslow
Our aim was to investigate whether molecular classification can be used to refine prognosis in grade 3 endometrial endometrioid carcinomas (EECs). Grade 3 EECs were classified into 4 subgroups: p53 abnormal, based on mutant-like immunostaining (p53abn); MMR deficient, based on loss of mismatch repair protein expression (MMRd); presence of POLE exonuclease domain hotspot mutation (POLE); no specific molecular profile (NSMP), in which none of these aberrations were present. Overall survival (OS) and recurrence-free survival (RFS) rates were compared using the Kaplan-Meier method (Log-rank test) and univariable and multivariable Cox proportional hazard models...
May 2018: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29489407/ct-features-of-ovarian-tumors-defining-key-differences-between-serous-borderline-tumors-and-low-grade-serous-carcinomas
#7
Stephanie Nougaret, Yulia Lakhman, Nicolas Molinari, Diana Feier, Chiara Scelzo, Hebert A Vargas, Ramon E Sosa, Hedvig Hricak, Robert A Soslow, Rachel N Grisham, Evis Sala
OBJECTIVE: The objective of our study was to investigate whether the CT features of serous borderline tumors (SBTs) differ from those of low-grade serous carcinomas (LGSCs) and to evaluate if mutation status is associated with distinct CT phenotypes. MATERIALS AND METHODS: This retrospective study included 59 women, 37 with SBT and 22 with LGSC, who underwent CT before primary surgical resection. Thirty of 59 patients were genetically profiled. Two radiologists (readers 1 and 2) independently and retrospectively reviewed CT examinations for qualitative features and quantified total tumor volumes (TTVs), solid tumor volumes (STVs), and solid proportion of ovarian masses...
February 28, 2018: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/29439179/evolving-roles-of-histologic-evaluation-and-molecular-genomic-profiling-in-the-management-of-endometrial-cancer
#8
REVIEW
Rajmohan Murali, Deborah F Delair, Sarah M Bean, Nadeem R Abu-Rustum, Robert A Soslow
Endometrial cancers are the most common gynecologic malignancies. The staging of endometrial cancer has evolved from a clinical-based system to a comprehensive surgical-pathologic approach that allows for better risk stratification and treatment planning. Over the past few years, use of NCCN's sentinel lymph node (SLN) mapping algorithm for the surgical staging of endometrial cancer has gained significant acceptance and is now commonly applied in many practices. However, pathologic evaluation of prognostic factors is beset by challenges, including the reproducibility of histologic classification and FIGO's grading, as well as the questionable clinical significance of low-volume tumor in SLNs...
February 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29248205/a-guided-tour-of-selected-issues-pertaining-to-metastatic-carcinomas-involving-or-originating-from-the-gynecologic-tract
#9
REVIEW
Robert A Soslow, Rajmohan Murali
No abstract text is available yet for this article.
March 2018: Seminars in Diagnostic Pathology
https://www.readbyqxmd.com/read/29246451/molecular-insights-into-the-classification-of-high-grade-endometrial-carcinoma
#10
REVIEW
Yaser R Hussein, Robert A Soslow
Endometrial carcinoma, which is associated with a mortality rate of approximately 20%, is the most common gynecological malignancy in the Western world. It is a heterogeneous disease, with multiple histotypes, each constituting a different disease entity. However, interobserver diagnostic agreement is suboptimal, particularly among the most lethal histotypes. Most recent data also indicate that histotype assignment is not independently associated with survival, while in contrast, clinicopathological risk stratification and genomic classification are significantly prognostic...
February 2018: Pathology
https://www.readbyqxmd.com/read/29192652/zc3h7b-bcor-high-grade-endometrial-stromal-sarcomas-a-report-of-17-cases-of-a-newly-defined-entity
#11
Natasha Lewis, Robert A Soslow, Deborah F Delair, Kay J Park, Rajmohan Murali, Travis J Hollmann, Ben Davidson, Francesca Micci, Ioannis Panagopoulos, Lien N Hoang, Javier A Arias-Stella, Esther Oliva, Robert H Young, Martee L Hensley, Mario M Leitao, Meera Hameed, Ryma Benayed, Marc Ladanyi, Denise Frosina, Achim A Jungbluth, Cristina R Antonescu, Sarah Chiang
High-grade endometrial stromal sarcoma likely encompasses underrecognized tumors harboring genetic abnormalities besides YWHAE-NUTM2 fusion. Triggered by three initial endometrial stromal sarcomas with ZC3H7B-BCOR fusion characterized by high-grade morphology and aggressive clinical behavior, we herein investigate the clinicopathologic features of this genetic subset by expanding the analysis to 17 such tumors. All of them occurred in adult women with a median age of 54 (range, 28-71) years. They were predominantly based in the endomyometrium and demonstrated tongue-like and/or pushing myometrial invasion...
December 1, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/29174566/the-roles-of-pathology-in-targeted-therapy-of-women-with-gynecologic-cancers
#12
REVIEW
Rajmohan Murali, Rachel N Grisham, Robert A Soslow
The role of the pathologist in the multidisciplinary management of women with gynecologic cancer has evolved substantially over the past decade. Pathologists' evaluation of parameters such as pathologic stage, histologic subtype, grade and microsatellite instability, and their identification of patients at risk for Lynch syndrome have become essential components of diagnosis, prognostic assessment and determination of optimal treatment of affected women. Despite the use of multimodality treatment and combination cytotoxic chemotherapy, the prognosis of women with advanced-stage gynecologic cancer is often poor...
January 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29135516/international-endocervical-adenocarcinoma-criteria-and-classification-iecc-a-new-pathogenetic-classification-for-invasive-adenocarcinomas-of-the-endocervix
#13
Simona Stolnicu, Iulia Barsan, Lien Hoang, Prusha Patel, Cristina Terinte, Anna Pesci, Sarit Aviel-Ronen, Takako Kiyokawa, Isabel Alvarado-Cabrero, Malcolm C Pike, Esther Oliva, Kay J Park, Robert A Soslow
We sought to classify endocervical adenocarcinomas (ECAs) based on morphologic features linked to etiology (ie, human papillomavirus [HPV] infection), unlike the World Health Organization 2014 classification. The International Endocervical Adenocarcinoma Criteria and Classification (IECC criteria), described herein, distinguishes between human papillomavirus-associated adenocarcinoma (HPVA), recognized by the presence of luminal mitoses and apoptosis seen at scanning magnification, and no or limited HPVA features (nonhuman papillomavirus-associated adenocarcinoma [NHPVA])...
February 2018: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29042553/molecular-analysis-of-high-grade-serous-ovarian-carcinoma-with-and-without-associated-serous-tubal-intra-epithelial-carcinoma
#14
Jennifer Ducie, Fanny Dao, Michael Considine, Narciso Olvera, Patricia A Shaw, Robert J Kurman, Ie-Ming Shih, Robert A Soslow, Leslie Cope, Douglas A Levine
Many high-grade serous carcinomas (HGSCs) of the pelvis are thought to originate in the distal portion of the fallopian tube. Serous tubal intra-epithelial carcinoma (STIC) lesions are the putative precursor to HGSC and identifiable in ~ 50% of advanced stage cases. To better understand the molecular etiology of HGSCs, we report a multi-center integrated genomic analysis of advanced stage tumors with and without STIC lesions and normal tissues. The most significant focal DNA SCNAs were shared between cases with and without STIC lesions...
October 17, 2017: Nature Communications
https://www.readbyqxmd.com/read/28965698/comparison-of-a-sentinel-lymph-node-mapping-algorithm-and-comprehensive-lymphadenectomy-in-the-detection-of-stage-iiic-endometrial-carcinoma-at-higher-risk-for-nodal-disease
#15
Jennifer A Ducie, Ane Gerda Zahl Eriksson, Narisha Ali, Michaela E McGree, Amy L Weaver, Giorgio Bogani, William A Cliby, Sean C Dowdy, Jamie N Bakkum-Gamez, Robert A Soslow, Gary L Keeney, Nadeem R Abu-Rustum, Andrea Mariani, Mario M Leitao
OBJECTIVE: To determine if a sentinel lymph node (SLN) mapping algorithm will detect metastatic nodal disease in patients with intermediate-/high-risk endometrial carcinoma. METHODS: Patients were identified and surgically staged at two collaborating institutions. The historical cohort (2004-2008) at one institution included patients undergoing complete pelvic and paraaortic lymphadenectomy to the renal veins (LND cohort). At the second institution an SLN mapping algorithm, including pathologic ultra-staging, was performed (2006-2013) (SLN cohort)...
December 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28863077/undifferentiated-endometrial-carcinomas-show-frequent-loss-of-core-switch-sucrose-nonfermentable-complex-proteins
#16
Martin Köbel, Lien N Hoang, Basile Tessier-Cloutier, Bo Meng, Robert A Soslow, Colin J R Stewart, Cheng-Han Lee
Undifferentiated endometrial carcinoma is an aggressive type of endometrial carcinoma that typically presents with advanced stage disease and rapid clinical progression. In contrast to dedifferentiated endometrial carcinoma, undifferentiated carcinoma lacks a concurrent differentiated (typically low-grade endometrioid) carcinoma component, though the undifferentiated component of dedifferentiated carcinoma is similar histologically and immunophenotypically to pure undifferentiated carcinoma. We recently identified 3 mutually exclusive mechanisms of switch/sucrose nonfermentable (SWI/SNF) complex inactivation (BRG1 inactivation, INI1 inactivation or ARID1A/ARID1B co-inactivation) that are associated with histologic dedifferentiation in the majority of dedifferentiated endometrial carcinoma...
January 2018: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28863066/inflammatory-pseudotumor-presenting-as-a-mesosalpingeal-mass
#17
Simona Stolnicu, Robert A Soslow
We describe a case in which the clinical and pathologic features of a mesosalpingeal mass led to a diagnosis of inflammatory pseudotumor, an unusual tumor found in a rare location. The differential diagnosis is rather broad and includes lesions ranging from Castleman disease to an immunoglobulin G4-related fibrosclerosing tumor. The patient is alive and well at last follow-up.
August 31, 2017: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/28718916/the-genetic-landscape-of-endometrial-clear-cell-carcinomas
#18
Deborah F DeLair, Kathleen A Burke, Pier Selenica, Raymond S Lim, Sasinya N Scott, Sumit Middha, Abhinita S Mohanty, Donavan T Cheng, Michael F Berger, Robert A Soslow, Britta Weigelt
Clear cell carcinoma of the endometrium is a rare type of endometrial cancer that is generally associated with an aggressive clinical behaviour. Here, we sought to define the repertoire of somatic genetic alterations in endometrial clear cell carcinomas (ECCs), and whether ECCs could be classified into the molecular subtypes described for endometrial endometrioid and serous carcinomas. We performed a rigorous histopathological review, immunohistochemical analysis and massively parallel sequencing targeting 300 cancer-related genes of 32 pure ECCs...
October 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28700432/novel-fumarate-hydratase-mutation-in-siblings-with-early-onset-uterine-leiomyomas-and-hereditary-leiomyomatosis-and-renal-cell-cancer-syndrome
#19
Vinay Gunnala, Nigel Pereira, Mohamad Irani, Debra Lilienthal, Edyta C Pirog, Robert Soslow, Thomas A Caputo, Rony Elias, Isaac Kligman, Zev Rosenwaks
Hereditary leiomyomatosis renal cell cancer syndrome is an autosomal dominant disorder characterized by uterine and cutaneous leiomyomas and increased predisposition to renal cell carcinoma, papillary type II. The syndrome is caused by heterozygous mutations to the fumarate hydratase (FH) gene located on chromosome 1. Affected females generally present with early onset, atypical uterine leiomyomas and cutaneous findings, however, delays in diagnosis are very common in patients with isolated uterine findings...
July 11, 2017: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/28664937/leiomyoma-with-bizarre-nuclei-a-morphological-immunohistochemical-and-molecular-analysis-of-31-cases
#20
Jennifer A Bennett, Britta Weigelt, Sarah Chiang, Pier Selenica, Ying-Bei Chen, Ann Bialik, Rui Bi, Anne M Schultheis, Raymond S Lim, Charlotte K Y Ng, Vicente Morales-Oyarvide, Robert H Young, Victor E Reuter, Robert A Soslow, Esther Oliva
Leiomyomas associated with hereditary leiomyomatosis and renal cell carcinoma syndrome and leiomyomas with bizarre nuclei often show overlapping morphological features, in particular cells with prominent eosinophilic nucleoli, perinucleolar halos, and eosinophilic cytoplasmic inclusions. Although hereditary leiomyomatosis and renal cell carcinoma syndrome is defined by fumarate hydratase (FH) germline mutations, resulting in S-(2-succino)-cysteine (2SC) formation, it is unknown whether leiomyomas with bizarre nuclei show similar alterations...
October 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
keyword
keyword
120516
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"